News stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the pharmaceutical company an impact score of 45.7093231151083 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- EVP\Chief Commercial Officer of Vertex Pharmaceuticals Inc / Ma (NASDAQ:VRTX), Arbuckle Stuart A, sells 4,250 shares worth $675,750 (empowerednews.net)
- Vertex’s Cystic Fibrosis Drug Given The Okay For Pediatric Use In Europe (benzinga.com)
- The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex (finance.yahoo.com)
- Vertex’s Cystic Fibrosis Drug Ok’d for Pediatric Use in EU (finance.yahoo.com)
- Analysts’ Recommendations for Bioverativ in January 2018 (finance.yahoo.com)
VRTX has been the subject of several research reports. Cowen reissued a “buy” rating and set a $200.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday, December 11th. Deutsche Bank initiated coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price objective for the company. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Royal Bank of Canada boosted their price objective on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Finally, Vetr cut shares of Vertex Pharmaceuticals to a “sell” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average target price of $175.89.
Vertex Pharmaceuticals (NASDAQ VRTX) traded down $0.47 on Friday, hitting $157.93. 1,561,110 shares of the company’s stock were exchanged, compared to its average volume of 1,530,000. The company has a market capitalization of $39,940.00, a price-to-earnings ratio of 202.47, a P/E/G ratio of 1.87 and a beta of 1.58. Vertex Pharmaceuticals has a fifty-two week low of $79.78 and a fifty-two week high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company’s revenue was up 39.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.16 earnings per share. equities research analysts expect that Vertex Pharmaceuticals will post 0.76 EPS for the current year.
In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 4,250 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $159.00, for a total value of $675,750.00. Following the completion of the transaction, the executive vice president now directly owns 46,202 shares in the company, valued at $7,346,118. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey M. Leiden sold 125,000 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the completion of the transaction, the chief executive officer now owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The disclosure for this sale can be found here. Over the last quarter, insiders sold 358,464 shares of company stock valued at $51,830,442. Company insiders own 1.80% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.